Resverlogix Corp.
International Steering Committee for RVX-208 IVUS Trial Formed
Published in Cardiovascular Device Liability Week, October 26th, 2008
"We are honored to have an experienced and highly esteemed group of internationally recognized cardiologists to lead this important IVUS atherosclerosis study," said Mr. Donald J. McCaffrey, President and CEO of Resverlogix. "ApoA-IMilano infusions have previously been shown to be the most efficient means to reduce atherosclerosis, we will now test the hypothesis that a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
More Articles from Cardiovascular Device Liability Week
- Glancy Binkow & Goldberg Llp
Glancy Binkow & Goldberg LLP, Who Filed the Initial Complaint Representing Shareholders of the Spectranetics Corporation, Announces Update to Shareholder Lawsuit - Abiomed Inc
Abiomed to Showcase Impella 2.5 Heart Recovery Device at TCT 2008 - Anesthesia
Research results from J.L. Downs and colleagues update understanding of aging - Aneurysm
Endovascular Aneurysm Repair Offers Better Results than Open Surgical Repair in High Risk Patients - Angina
Research from N. Shinozaki and co-researchers in the area of angina described - Angiogenesis
Research from Zhejiang University yields new data on angiogenesis - More from this issue of Cardiovascular Device Liability Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
